Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

X Genomics Inc . (NASDAQ:TXG) reported its Q4 2024 earnings, revealing a larger-than-expected loss per share and a decline in revenue compared to the previous year. The company posted an EPS of -$0.40 ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales ...

Many studies have used single-cell RNA sequencing (scRNA-seq) to infer gene regulatory networks (GRNs), which are crucial for ...

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance understanding of cellular ...

The Chan Zuckerberg Initiative (CZI), in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading ...

Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

The global single cell multiomics market is set to experience a remarkable growth trajectory, projected to reach $14,369.5 million by 2031, with an impressive Compound Annual Growth Rate (CAGR) of ...

Technological Innovation: The rapid pace of technological innovation in single cell isolation, sequencing, and analysis techniques is a primary driver of market growth. These advancements have ...